It was a dramatic positive. The pie is bigger and the revenue slope is steeper.

It was not a blow-your-socks-off offer.

This dramatically raises the market potential.

We anticipate Amgen to serve Roche an official court summons towards 3/06 timeframe upon which Roche will respond and the patent litigation suit will be in process. Ultimately, we continue to believe that Amgen will successfully defend its erythropoietin patents and that CERA will be found to have infringed.

One of Chiron's issues [is] it really never had a strong identify with the biotech investing community.

They had an absolutely blowout second quarter.